Comparison between equimolar- and skewed-response assays of prostate specific antigen: Is there an influence on the clinical significance when measuring total serum prostate specific antigen?

Annals of Clinical Biochemistry

Volumn 33, Issue 3, 1996, Pages 209-214

  Jung, Klaus ^a   Lein, Michael ^a   Schnorr, Dietmar ^a   Brux, Brigitte ^a   Henke, Wolfgang ^a   Loening, Stefan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Benign prostate hyperplasia; Prostate cancer; Receiver operation curve; Tumour marker

Indexed keywords

PROSTATE ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSIS; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 0029979142     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329603300306     Document Type: Article

References (17)

1. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993; 39: 2483-91
2. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-15
3. 1-antichymotrypsin. Clin Chem 1991; 37: 1618-25
4. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
5. 1-antichymotrypsin (PSA/ACT) and uncomplexed PSA in serum from patients with benign prostate hypertrophy (BPH) and prostate cancer (PCA) using dual monoclonal assays. J Urol 1993; 149: 333A
6. Tillyer CR, Konings M, Gobin PT, Iqbal J. Disagreement between the Roche Cobas Core and Hybritech TANDEM-E PSA assays when measuring free, complexed and total serum prostate specific antigen. Ann Clin Biochem 1994; 31: 501-5
7. Strobel SA, Sokoloff RK, Wolfert RL, Rittenhouse HG. Multiple forms of prostate-specific antigen in serum measured differently in equimolar-and skewed-response assays. Clin Chem 1995. 41: 125-6
8. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurement from two analytical methods. J Clin Chem Clin Biochem 1988; 21 709-20
9. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-77
10. Hanley JA, NcNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36
11. 1-antichymotrypsin bound PSA. Clin Chem 1994; 40: 1009
12. Wu JT. Assay for prostate specific antigen (PSA): problems and possible solutions. J Clin Lab Anal 1994; 8: 51-80
13. Nakamura RM. Current and future directions regarding quality assurance and standardization of prostate specific antigen immunoassays. Cancer 1994; 74: 1655-9
14. Bluestein B, Zhou A, Tewari P, Comerci C, Schubert W, Larsen F. Multi-site clinical evaluation of an automated chemiluminescent immunoassay for prostate specific antigen (ACS™ PSA). J Tumor Marker Oncol 1992; 7: 41-60
15. Stamey TA, Prestigiacomo AF, Chen Z. Standardization of immunoassays for prostate specific antigen. A different view based on experimental observations. Cancer 1994; 74: 1662-6
16. Bluestein BI, Tewari PC, Weitz S, Zhou A. Multiple forms of prostate-specific antigen in serum measured differently in equimolar-and skewed-response assays. Clin Chem 1995; 41: 126-7
17. Christensen SE, Zhang P, Wang T, Stephenson R, Wu J. The effect of prostate specific antigen (PSA) complex formation on current PSA assays. Clin Chem 1994; 40: 1011